80% Effective in adults, no risk of blood clots

The good news came about the vaccine amid concerns about the effectiveness of the AstraZeneca covid-19 vaccine. After testing the vaccine in humans in the United States, AstraZeneca said their vaccine was 80 percent effective in preventing Covid-19 in older people. And it is 100% effective in preventing serious illness or hospitalization. At the same time, there was no evidence that the vaccine increased the risk of blood clots. This information was given on Monday after the third stage (final stage) test of tick in human body in the United States.

The vaccine was jointly developed by Oxford University with the UK-Sweden-based pharmaceutical company AstraZeneca. More tests have been performed on the human body before to prove the effectiveness of the vaccine. However, due to a lack of information about older people taking part in these tests, some countries oppose the use of the estrogen vaccine in older people. The big controversy over the AstraZeneca vaccine began earlier this month. Several countries have suspended vaccinations for fear of blood clots after receiving the vaccine. However, no evidence of blood clots was found after the vaccination, AstraZeneca said in a statement last week. The vaccine is safe, according to the World Health Organization, the European Medicines Agency.

AstraZeneca vaccines have been tested in humans around the world, but have not yet been approved in the United States. It is believed that the positive results of the test in the human body in the country will pave the way for the approval of the vaccine.

In a statement, AstraZeneca said 32,449 people in the United States had taken the third stage of their vaccine. Two-thirds of them have been vaccinated. About 20 percent of them are 65 or older, and about 60 percent are at high risk for Covid-19. They suffer from diabetes, obesity and heart disease. The vaccine is 79 percent effective in treating coronavirus symptoms in people of all ages. The vaccine is 100 percent effective for critically ill and hospitalized patients.

AstraZeneca conducted the test jointly with Columbia University and the University of Rochester in the United States. Anne Falsey, a professor of medicine at the University of Rochester and deputy head of the Ticker Efficacy Test, said the test supported the results of previous tests. The effectiveness of the AstraZeneca vaccine in people over 65 has been shown to be very encouraging. As a result, the test recognizes the AstraZeneca vaccine as a much-needed vaccine. At the same time reassuring the elderly that the vaccine can protect all adults from the virus.

In a statement, AstraZeneca added that the "Neutral Board for Monitoring Vaccine Tests" found no evidence of a risk of blood clots in vaccinated individuals (21,583 people).